Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential

Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential

With a considerable patient population and continued government focus on lowering national smoking rates, the nicotine dependence market represents a lucrative opportunity for pharmaceutical companies. With strong uptake since launch in 2006 of Pfizer's Chantix (varenicline), the seven major prescription nicotine dependence market was estimated to total $1.35 billion in 2008.

Scope

*Patient potential analysis across the seven major markets, Brazil, Russia, India, and China as well as assessment of clinical unmet needs.

*Analysis of the prescription and over-the-counter pharmaceutical markets for anti-smoking products from 20042008 in the seven major regions.

*Case study review of Chantix including historic sales data analysis, opinion leader view on its safety and prospects, with scenario forecasts to 2018.

*In depth pipeline analysis, with detailed profiles of late-stage nicotine vaccines that feed into a region-specific market projection to 2018.

Highlights

Although US and UK smoking rates have fallen over the past decade, demand for effective anti-smoking methods remains a significant requirement. Additionally, with higher smoking rates and evolving government antismoking initiatives, the substantial smoking populations in China, India and Russia represent a real market opportunity.

Datamonitor anticipates Pfizer to be successful in reinstating prescriber and patient confidence in Chantix by establishing a favorable risk-benefit ratio and emphasizing the requirement for improved patient screening and follow-up. Under this assumption, sales of Chantix are forecast to return to growth.

Through the late-stage development of Nabi's NicVAX and Novartis and Cytos's NIC-002, nicotine vaccines remain a key focus of the nicotine dependence pipeline. With the first major market launch predicted for 2012, Datamonitor forecasts the two vaccines to generate strong annual revenues by 2018.

Reasons to Purchase

*Appreciate the nicotine dependence patient potential and where future geographical market opportunities exist.

*Benchmark key late-stage pipeline nicotine dependence projects against current market leading brands, supported by insight from key opinion leaders.

*Quantify the future market landscape with sales forecasts of marketed, generics, and key late-stage pipeline drugs to 2018 in the US, 5EU and Japan.

23-Mar-09 PDF & SlidePack & DataPack Pages: 159

Table of Contents
Price: $15,200.00 / €10,066.96

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions